Summary
Although the factors contributing to the progression of prostate cancer (PC) remain incompletely understood, androgens have long been recognized to play a central role in this process. Upon entering PC cells, androgens bind to a cognate nuclear receptor, the androgen receptor (AR). The activated AR translocates to the nucleus, binds as a dimer to androgen response elements (AREs) in the promoter of target genes, where it recruits the coactivator proteins necessary for the formation of a productive transcriptional complex, an event crucial for PC cell viability. For many decades, the androgen dependency of PCs has been exploited therapeutically by androgen ablation strategies. Although initially successful, these forms of therapy almost inevitably fail eventually, and an androgen depletion independent (ADI) disease emerges, for which currently no cure is available. Studies from our laboratory and others demonstrate that despite low circulating levels of functional androgens, the AR is critical for the proliferation and survival of ADI PC cells. Recent data indicate that alterations in the expression and/or activity of AR coactivator proteins occur during PC progression that can foster ADI activation of the AR. Here, we have investigated the role of the coactivator p300 in AR transcriptional activity and progression of PC.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Grossmann ME, Huang H, Tindall DJ (2001) Androgen receptor signaling in androgen-refractory prostate cancer. J Natl Cancer Inst 93:1687–97.
Debes JD, Tindall DJ (2004) Mechanisms of androgen-refractory prostate cancer. N Engl J Med 351:1488–90.
Heinlein CA, Chang C (2002) Androgen receptor (AR) coregulators: an overview. Endocr Rev 23:175–200.
Heemers HV, Tindall DJ (2005) Androgen receptor coregulatory proteins as potential therapeutic targets in the treatment of prostate cancer. Curr Cancer Ther Rev 1:175–86.
Kalkhoven E (2004) CBP and p300: HATs for different occasions. Biochem Pharmacol 68:1145–55.
Fu M, Wang C, Reutens AT, et al. (2000) p300 and p300/cAMP-response element-binding protein-associated factor acetylate the androgen receptor at sites governing hormone-dependent transactivation. J Biol Chem 275:20853–60.
Fu M, Rao M, Wang C, et al. (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563–75.
Debes JD, Sebo TJ, Lohse CM, et al. (2003) p300 in prostate cancer proliferation and progression. Cancer Res 63:7638–40.
Culig Z, Steiner H, Bartsch G, et al. (2005) Interleukin-6 regulation of prostate cancer cell growth. J Cell Biochem 95:497–505.
Debes JD, Schmidt LJ, Huang H, et al. (2002) p300 mediates androgen-independent transactivation of the androgen receptor by interleukin 6. Cancer Res 62:5632–6.
Debes JD, Sebo TJ, Heemers HV, et al. (2005) p300 modulates nuclear morphology in prostate cancer. Cancer Res 65:708–12.
Gong J, Zhu J, Goodman OB, Jr, et al. (2006) Activation of p300 histone acetyltransferase activity and acetylation of the androgen receptor by bombesin in prostate cancer cells. Oncogene. 25:2011–21.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2008 Springer
About this chapter
Cite this chapter
Heemers, H.V., Debes, J.D., Tindall, D.J. (2008). The Role of the Transcriptional Coactivator p300 in Prostate Cancer Progression. In: Li, J.J., Li, S.A., Mohla, S., Rochefort, H., Maudelonde, T. (eds) Hormonal Carcinogenesis V. Advances in Experimental Medicine and Biology, vol 617. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69080-3_54
Download citation
DOI: https://doi.org/10.1007/978-0-387-69080-3_54
Publisher Name: Springer, New York, NY
Print ISBN: 978-0-387-69078-0
Online ISBN: 978-0-387-69080-3
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)